← Back
Data updated: Mar 10, 2026
INCYTE CORP
OncologyDermatologyImmunology
INCYTE CORP is a specialty pharmaceutical company focused on Oncology, Dermatology, Immunology. Key products include JAKAFI.
2011
Since
5
Drugs
-
Trials
5
Approved (2yr)
Key Drugs
Recent Activity
ZYNYZ 2025-12-17
Efficacy
OPZELURA 2025-09-18
Efficacy
ZYNYZ 2025-05-15
Efficacy
NIKTIMVO 2024-08-14
Type 1 - New Molecular Entity
ZYNYZ 2024-04-22
Labeling
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Oncology 73%
2 drugs Phase 3: 18 Phase 2: 29 Phase 1: 53
Dermatology 20%
1 drugs Phase 3: 8 Phase 2: 6 Phase 1: 4
Immunology 3%
0 drugs Phase 3: 1 Phase 2: 2
Gastroenterology 3%
0 drugs Phase 2: 1 Phase 1: 5
Respiratory 1%
0 drugs Phase 2: 1
Pipeline Strength Pro
Loading...
Competitors Pro
Pfizer big-pharma
Oncology, Dermatology, Immunology, Gastroenterology
Novartis big-pharma
Oncology, Immunology, Respiratory
Gilead Sciences biotech
Oncology, Immunology, Gastroenterology, Respiratory
MALLINCKRODT specialty
Gastroenterology, Dermatology, Immunology, Respiratory
GSK big-pharma
Respiratory, Oncology, Immunology